New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 23, 2014
15:44 EDTCELGCelgene releases new research findings on OTEZLA
Celgene Corporation released new research findings on OTEZLA, apremilast, the company’s oral, selective inhibitor of phosphodiesterase 4, PDE4, from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology, AAD, Annual Meeting in Denver, CO. ESTEEM 1 demonstrated a stable mean PASI improvement of 81 to 88% between weeks 32 and 52 for those patients who were treated for 52 weeks with OTEZLA 30 mg BID and who achieved a PASI-75 score at week 32 . These data are consistent with the mean PASI-75 improvement observed between weeks 16 and 32. In the same group of patients, OTEZLA 30 mg BID continued to demonstrate improvements in difficult-to-treat areas affected by plaque psoriasis...In ESTEEM 2, a significantly higher percentage of patients receiving OTEZLA 30 mg BID achieved a PASI-75 response at week 16, primary endpoint, compared with patients who received placebo. Statistical significance at week 16 was also demonstrated for the major secondary endpoint, static Physician Global Assessment, sPGA, score of clear or almost clear. The beneficial effects of OTEZLA on psoriasis in difficult-to-treat areas of scalp, nails, palms and soles were also demonstrated in ESTEEM 2. After 16 weeks of treatment, OTEZLA 30 mg BID demonstrated significantly higher response rates versus placebo for psoriasis affecting the scalp...“Psoriasis of the nails, scalp and palmoplantar regions is very difficult to treat and can be debilitating for individuals dealing with this chronic disease," said Jennifer Cather, MD, Modern Research Associates, Dallas, Texas. “Results from the 52-week analysis of the ESTEEM program suggest that early responses seen with OTEZLA treatment in multiple efficacy endpoints of plaque psoriasis, including difficult to treat areas, are durable over time. Together with the observed long-term consistent safety and tolerability profile, these findings are encouraging.” A separate analysis of long-term safety and tolerability data from ESTEEM 1 identified no new or unexpected adverse events (AEs) for patients treated with OTEZLA compared with results at week 16...No new or unexpected AEs were identified for patients treated with OTEZLA in ESTEEM 2.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
07:37 EDTCELGCelgene removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
February 25, 2015
13:44 EDTCELGCelgene price target raised to $155 from $130 at Argus
Argus increased its price target on Celgene as the firm thinks the company is "well on its way" to meeting its growth targets. The firm thinks the company reported strong Q4 results and keeps a Buy rating on the shares.
February 24, 2015
08:04 EDTCELGCelgene reports Abraxane now reimbursed in Italy as first-line treatment
Celgene International Sŕrl, a wholly owned subsidiary of Celgene Corporation, announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANE -- paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel -- in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. The reimbursement decision has been published in the Italian Official Gazette no. 30, dated February 6, 2015.
07:31 EDTCELGRBC Capital to hold a conference
Subscribe for More Information
February 20, 2015
16:03 EDTCELGOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information
February 18, 2015
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use